BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Onyx Pharmaceuticals Inc.

Headquarters: South San Francisco, CA, United States
Website: N/A
Year Founded: 1992
Status: Acquired

BioCentury | Mar 25, 2024
Finance

Now a biotech pure-play, Avalon riding ‘sweat equity’ model to outsized returns

A smaller fund size can lead to a higher multiple — especially when a portfolio company such as Janux delivers promising early data
BioCentury | May 9, 2023
Management Tracks

Laronde’s Cagnoni to head R&D at Incyte

Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
BioCentury | May 3, 2023
Management Tracks

Culture and trust: How Cerevel’s Coles picked Renaud for CEO 

Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role
BioCentury | Mar 11, 2023
Emerging Company Profile

Opna Bio: targeting FMRP to treat cancer

Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Feb 24, 2022
Management Tracks

Philip to succeed Marrazzo at Spark

Plus LaCaze joins Mnemo and updates from Sumitomo, Veracyte, Totus and more
BioCentury | Jan 13, 2022
Management Tracks

Carino joins White House’s office of science and technology policy

Plus Foster becomes venture partner and updates from Norwest, TCR2, PTC and more
BioCentury | Nov 9, 2021
Data Byte

A tally of female CEOs at major biopharmas 

Spoiler: you’ll soon need two hands to count them
BioCentury | Mar 4, 2021
Deals

Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout

Target-validating data in genetically-defined cancer spurs buyout
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche
Items per page:
1 - 10 of 911
Username